Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for FibroBiologics Inc. (FBLG : NSDQ)

• Company Description    FibroBiologics Inc. is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics Inc. is based in HOUSTON. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $0.65 Daily Weekly Monthly 20 Day Moving Average: 511,178 shares Shares Outstanding: 39.68 (millions) Market Capitalization: $25.75 (millions) Beta: -0.78 52 Week High: $5.62 52 Week Low: $0.58 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -25.62% -28.40% 12 Week -45.46% -54.13% Year To Date -67.55% -69.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 455 E. MEDICAL CENTER BLVD SUITE 300 - HOUSTON,TX 77598 USA ph: 281-651-5150 fax: - fibrobiologicsir@russopr.com http://www.fibrobiologics.com

• General Corporate Information    Officers Pete O'Heeron - Chief Executive Officer and Chairperson Robert E. Hoffman - Interim Chief Financial Officer and Director Richard Cilento - Director Stacy Coen - Director Matthew Link - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 31573L105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 39.68 Most Recent Split Date: (:1) Beta: -0.78 Market Capitalization: $25.75 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 10.57 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 48.15% vs. Previous Quarter: -55.56% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -1,022.04 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -117.56 12/31/24 - -147.22 Current Ratio 06/30/25 - - 03/31/25 - 1.14 12/31/24 - 1.12 Quick Ratio 06/30/25 - - 03/31/25 - 1.14 12/31/24 - 1.12 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.06 12/31/24 - 0.08 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©